Status:
COMPLETED
Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Malaria
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Riamet® or Malarone® are both recommended as the first line treatment for uncomplicated malaria in France, according to the French consensus Conference revised in 2007 on the treatment of imported mal...
Detailed Description
Background : RIAMET® or Malarone® are both recommended as the first line treatment for uncomplicated malaria in France, according to the French consensus Conference revised in 2007 on the treatment of...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- subjects aged more than 18,
- back from an endemic area with a positive diagnosis of Plasmodium falciparum by microscopic blood (thin and thick film) examination,
- absence of any severe manifestation according to the WHO definition of severe falciparum malaria
- EXCLUSION CRITERIA:
- pregnancy,
- ECG abnormality,
- contraindication to treatment,
- previous anti-malaric treatment within 30 days,
- unable to come back at J3, J7 and J28,
- unwilling to consent to participate
Exclusion
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
317 Patients enrolled
Trial Details
Trial ID
NCT01150344
Start Date
July 1 2010
End Date
November 1 2015
Last Update
December 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Avicenne
Bobigny, Seine St Denis, France, 93000